FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:800-808 February 22, 2007 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Gazdar, A. F. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis, tumor progression, and the response of non–small-cell lung cancer to treatment.

Methods We developed an automated quantitative determination of the RRM1 protein in routinely processed histologic specimens. In these specimens, we measured the expression of RRM1 and two other proteins that are relevant to non–small-cell lung cancer: the excision repair cross-complementation group 1 (ERCC1) protein and the phosphatase and tensin homologue (PTEN). We compared the results with the clinical outcomes in 187 patients with early-stage non–small-cell lung cancer who had received only surgical treatment.

Results RRM1 expression correlated with the expression of ERCC1 (P<0.001) but not with the expression of PTEN (P=0.37). The median disease-free survival exceeded 120 months in the group of patients with tumors that had high expression of RRM1 and was 54.5 months in the group with low expression of RRM1 (hazard ratio for disease progression or death in the high-expression group, 0.46; P=0.004). The overall survival was more than 120 months for patients with tumors with high expression of RRM1 and 60.2 months for those with low expression of RRM1 (hazard ratio for death, 0.61; P=0.02). Among these 187 patients, the survival advantage was limited to the 30% of patients with tumors that had a high expression of both RRM1 and ERCC1.

Conclusions RRM1 and ERCC1 are determinants of survival after surgical treatment of early-stage, non–small-cell lung cancer.

Source Information

From the Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Address reprint requests to Dr. Bepler at the H. Lee Moffitt Cancer Center and Research Institute, MRC-4W, Rm. 4046, 12902 Magnolia Dr., Tampa, FL 33612-9497, or at beplerg{at}moffitt.usf.edu.

Full Text of this Article

Related Letters:

ERCC1 and Non–Small-Cell Lung Cancer
Niedernhofer L. J., Bhagwat N., Wood R. D., Zhou S.-F., Panasci L., Cohen V., Bepler G., Zheng Z., Chen T.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2538-2541, Jun 14, 2007. Correspondence

This article has been cited by other articles:

• Sorrentino, C., Di Carlo, E. (2009). Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype. Am. J. Respir. Crit. Care Med. 180: 769-779 [Abstract] [Full Text]  
• Holm, B., Mellemgaard, A., Skov, T., Skov, B. G. (2009). Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine. JCO 27: 4254-4259 [Abstract] [Full Text]  
• Ronchi, C. L, Sbiera, S., Kraus, L., Wortmann, S., Johanssen, S., Adam, P., Willenberg, H. S, Hahner, S., Allolio, B., Fassnacht, M. (2009). Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16: 907-918 [Abstract] [Full Text]  
• Bhagwat, N. R., Roginskaya, V. Y., Acquafondata, M. B., Dhir, R., Wood, R. D., Niedernhofer, L. J. (2009). Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human Tissue. Cancer Res. 69: 6831-6838 [Abstract] [Full Text]  
• Planchard, D., Domont, J., Taranchon, E., Monnet, I., Tredaniel, J., Caliandro, R., Validire, P., Besse, B., Soria, J.-C., Fouret, P. (2009). The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol 20: 1257-1263 [Abstract] [Full Text]  
• Yeatman, T. J. (2009). Predictive Biomarkers: Identification and Verification. JCO 27: 2743-2744 [Full Text]  
• Chhatwani, L., Cabebe, E., Wakelee, H. A. (2009). Adjuvant Treatment of Resected Lung Cancer. Proc Am Thorac Soc 6: 194-200 [Abstract] [Full Text]  
• Sculier, J-P., Moro-Sibilot, D. (2009). First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33: 915-930 [Abstract] [Full Text]  
• Haas, A. R. (2009). Infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration. Eur Respir J 33: 935-938 [Abstract] [Full Text]  
• Ceppi, P., Novello, S., Cambieri, A., Longo, M., Monica, V., Lo Iacono, M., Giaj-Levra, M., Saviozzi, S., Volante, M., Papotti, M., Scagliotti, G. (2009). Polymerase {eta} mRNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Clin. Cancer Res. 15: 1039-1045 [Abstract] [Full Text]  
• Scagliotti, G. V., Ceppi, P., Novello, S., Papotti, M. (2009). Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology. Am Soc Clin Oncol Ed Book 2009: 431-435 [Abstract] [Full Text]  
• Kim, H.-T., Lee, J.-E., Shin, E.-S., Yoo, Y.-K., Cho, J.-H., Yun, M.-H., Kim, Y.-H., Kim, S.-K., Kim, H.-J., Jang, T.-W., Kwak, S.-M., Kim, C.-S., Ryu, J.-S. (2008). Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. JCO 26: 5972-5979 [Abstract] [Full Text]  
• Besse, B., Le Chevalier, T. (2008). Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect?. JCO 26: 5014-5017 [Full Text]  
• Fatima, N., Yi, M., Ajaz, S., Stephens, R. M., Stauffer, S., Greenwald, P., Munroe, D. J., Ali, I. U. (2008). Altered Gene Expression Profiles Define Pathways in Colorectal Cancer Cell Lines Affected by Celecoxib. Cancer Epidemiol. Biomarkers Prev. 17: 3051-3061 [Abstract] [Full Text]  
• Berhoune, M., Banu, E., Scotte, F., Prognon, P., Oudard, S., Bonan, B. (2008). Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer. The Annals of Pharmacotherapy 42: 1640-1652 [Abstract] [Full Text]  
• Koomen, J. M., Haura, E. B., Bepler, G., Sutphen, R., Remily-Wood, E. R., Benson, K., Hussein, M., Hazlehurst, L. A., Yeatman, T. J., Hildreth, L. T., Sellers, T. A., Jacobsen, P. B., Fenstermacher, D. A., Dalton, W. S. (2008). Proteomic Contributions to Personalized Cancer Care. Mol. Cell. Proteomics 7: 1780-1794 [Abstract] [Full Text]  
• Herbst, R. S., Heymach, J. V., Lippman, S. M. (2008). Lung Cancer. NEJM 359: 1367-1380 [Full Text]  
• Yeatman, T. J., Mule, J., Dalton, W. S., Sullivan, D. (2008). On the Eve of Personalized Medicine in Oncology. Cancer Res. 68: 7250-7252 [Full Text]  
• Einhorn, L. H. (2008). First-Line Chemotherapy for Non-Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?. JCO 26: 3485-3486 [Full Text]  
• Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y. H., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H. Y., Lee, G. H., Choi, K. D., Kim, S.-B. (2008). Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy. Clin. Cancer Res. 14: 4225-4231 [Abstract] [Full Text]  
• Khuri, F. R., Roman, J. (2008). From Nihilism to Individualism: The Evolution of Lung Cancer Therapy. Am. J. Respir. Crit. Care Med. 177: 1299-1300 [Full Text]  
• Kim, S.-O., Jeong, J.-Y., Kim, M.-R., Cho, H.-J., Ju, J.-Y., Kwon, Y.-S., Oh, I.-J., Kim, K.-S., Kim, Y.-I., Lim, S.-C., Kim, Y.-C. (2008). Efficacy of Gemcitabine in Patients with Non-Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene. Clin. Cancer Res. 14: 3083-3088 [Abstract] [Full Text]  
• Breen, D., Barlesi, F. (2008). The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 33: 805-811 [Abstract] [Full Text]  
• Yu, D., Zhang, X., Liu, J., Yuan, P., Tan, W., Guo, Y., Sun, T., Zhao, D., Yang, M., Liu, J., Xu, B., Lin, D. (2008). Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis. Clin. Cancer Res. 14: 2878-2886 [Abstract] [Full Text]  
• Xu, X., Page, J. L., Surtees, J. A., Liu, H., Lagedrost, S., Lu, Y., Bronson, R., Alani, E., Nikitin, A. Yu., Weiss, R. S. (2008). Broad Overexpression of Ribonucleotide Reductase Genes in Mice Specifically Induces Lung Neoplasms. Cancer Res. 68: 2652-2660 [Abstract] [Full Text]  
• Sun, Z., Wigle, D. A., Yang, P. (2008). Non-Overlapping and Non-Cell-Type-Specific Gene Expression Signatures Predict Lung Cancer Survival. JCO 26: 877-883 [Abstract] [Full Text]  
• Olaussen, K. A., Fouret, P., Kroemer, G. (2007). ERCC1-Specific Immunostaining in Non-Small-Cell Lung Cancer. NEJM 357: 1559-1561 [Full Text]  
• Soria, J.-C. (2007). ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial. JCO 25: 2648-2649 [Full Text]  
• Simon, G., Sharma, A., Li, X., Hazelton, T., Walsh, F., Williams, C., Chiappori, A., Haura, E., Tanvetyanon, T., Antonia, S., Cantor, A., Bepler, G. (2007). Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer. JCO 25: 2741-2746 [Abstract] [Full Text]  
• Niedernhofer, L. J., Bhagwat, N., Wood, R. D., Zhou, S.-F., Panasci, L., Cohen, V., Bepler, G., Zheng, Z., Chen, T. (2007). ERCC1 and Non-Small-Cell Lung Cancer. NEJM 356: 2538-2541 [Full Text]  
• Cosgrove, J. (2007). Using molecular markers as a means of predicting prognosis and outcomes in the treatment of lung cancer. Thorax 62: 535-535 [Full Text]